Welcome to our dedicated page for Bioxytran SEC filings (Ticker: BIXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Bioxytran’s dense biotech disclosures can feel like wading through lab notebooks. Early-stage trials, galectin research, and oxygen-carrier data crowd every report, making it hard to spot the cash runway or the next clinical milestone. Stock Titan solves that problem by delivering AI-powered summaries that translate Bioxytran SEC filings into plain English, so you can focus on whether BXT-25 is on schedule and how insider confidence is shifting.
Need specifics? Our real-time feed posts every document the moment it hits EDGAR—whether it is a Bioxytran quarterly earnings report 10-Q filing detailing R&D spend, an 8-K material events explained notice on trial results, or a Bioxytran proxy statement executive compensation filing outlining stock-option triggers. Interactive dashboards surface Bioxytran insider trading Form 4 transactions within minutes, complete with alerts for any Bioxytran executive stock transactions Form 4. If you are searching for the full story behind dilution risk or partnership terms, our platform connects each line item to contextual commentary and links to prior disclosures.
Whether you type “Bioxytran SEC filings explained simply” or “understanding Bioxytran SEC documents with AI,” you land on the same advantage: concise takeaways, side-by-side comparisons, and keyword search across every form. Investors routinely use these tools to:
- Track cash burn trends through 10-Q and 10-K data (Bioxytran annual report 10-K simplified)
- Monitor Bioxytran Form 4 insider transactions real-time for patterns ahead of trial readouts
- Review Bioxytran earnings report filing analysis to gauge funding needs before the next Phase II
Bioxytran, Inc. (BIXT) reported insider share purchases by director Alan Hoberman. On 08/12/2025, he acquired 10,417 shares of preferred stock at $0.485 per share, bringing his preferred holdings to 377,619 shares. On 11/14/2025, he bought an additional 38,588 preferred shares at $0.35 per share, increasing his total preferred holdings to 416,207 shares. On 11/18/2025, he purchased 210,000 shares of common stock at $0.60 per share and held 210,000 common shares afterward. All positions are reported as held directly by the insider.
Bioxytran, Inc. director reports preferred share purchases
A director of Bioxytran, Inc. (BIXT) filed a Form 4 disclosing open-market style acquisitions of the company’s preferred stock. On 08/12/2025, the reporting person acquired 10,417 preferred shares at a price of $0.485 per share. On 11/14/2025, the same person acquired an additional 38,588 preferred shares at a price of $0.35 per share.
After these transactions, the director beneficially owns 203,688 preferred shares, held directly. The filing does not list any derivative securities such as options or warrants, indicating the reported holdings are solely in the form of non-derivative preferred stock.
Bioxytran, Inc. (BIXT) reported insider purchases by a company director. On 08/12/2025, the director acquired 10,417 preferred shares at a price of $0.485 per share. On 11/14/2025, the same director acquired an additional 38,588 preferred shares at a price of $0.35 per share. Following these transactions, the director beneficially owned 379,177 preferred shares, held in direct ownership.
Bioxytran, Inc. (BIXT) reported an insider equity transaction by a director on a Form 4. On 11/14/2025, the director acquired 38,588 preferred shares at a price of $0.35 per share. Following this transaction, the director beneficially owned 372,580 shares, held as a direct ownership position. The filing was made by a single reporting person in the capacity of director, and no derivative securities transactions were reported.
Bioxytran, Inc. insider David Platt, who serves as CEO, director, and a 10% owner, reported changes in his indirect holdings of preferred stock on a Form 4/A. On 10/24/2024, 14,085,410 preferred shares held through NDPD Pharma were returned to treasury and cancelled. On the same date, 11,433,448 preferred shares were issued as payment for the sale of NDPD to Bioxytran, leaving Platt with 20,038,903 preferred shares beneficially owned indirectly through NDPD Pharma. The filing consolidates NDPD Pharma’s Bioxytran holdings under Platt’s indirect ownership.
Bioxytran, Inc. (BIXT) reported an amended insider transaction for Chief Commercial Officer and director Michael Sheikh. On 10/25/2024, he acquired 6,614,720 common shares of Bioxytran at a price of $0.545 per share, reported as an acquisition. After this transaction, he beneficially owned 8,214,720 shares, held directly. The filing explains that these shares were issued as payment for the sale of NDPD Pharma to Bioxytran, meaning the consideration for that business sale was paid in Bioxytran stock rather than cash.
Bioxytran, Inc. insider Ola Soderquist, who serves as CFO and is a 10% owner, reported multiple equity transactions dated 10/25/2024. He acquired 10,069,396 shares of preferred stock at $0.545 per share, bringing his beneficial ownership in that class to 13,976,456 preferred shares. He also acquired an additional 100,000 preferred shares at $0.005 per share, after which he held 13,876,456 preferred shares. In addition, he acquired 500,000 shares of common stock at $0.001 per share and held 500,000 common shares directly after the transaction. The filing states that some shares were issued as payment for the sale of NDPD Pharma to Bioxytran and that there was a 1:5 exchange of preferred stock into common stock.
Bioxytran, Inc. filed its Q3 2025 report, highlighting continued losses and tight liquidity. The company posted a Q3 net loss of
Total assets were
Common shares outstanding were 88,992,243 and preferred shares outstanding were 43,429,639 as of
FAQ
What is the current stock price of Bioxytran (BIXT)?
What is the market cap of Bioxytran (BIXT)?
